Patents by Inventor Roch Thibert

Roch Thibert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
    Publication number: 20260102350
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Application
    Filed: September 25, 2025
    Publication date: April 16, 2026
    Inventors: Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT
  • Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
    Patent number: 12558317
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: December 21, 2023
    Date of Patent: February 24, 2026
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto
    Patent number: 12151998
    Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: November 26, 2024
    Assignee: The Regents of the University of Michigan
    Inventors: Stephen Warren Hunt, III, Martin Douglas Phillips, Robert Matunas, Herman Chen, Aimesther Betancourt, Charles Uzarama, Roch Thibert
  • SOLUBLE PHARMACEUTICAL COMPOSITIONS COMPRISING SALTS OF DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND
    Publication number: 20240366616
    Abstract: Disclosed are pharmaceutical compositions comprising a salt of a compound having the formula: and one or more excipients, wherein the pharmaceutical composition avoids inducing disproportionation of the salt of the compound.
    Type: Application
    Filed: July 20, 2022
    Publication date: November 7, 2024
    Applicants: Mineralys Therapeutics, Inc., Mitsubishi Tanabe Pharma Corporation
    Inventors: Robert McKean, Roch Thibert, Elizabeth Vadas, Yoshinori Ohashi, Fuminori Ozaki, Hiroki Ohshima, Hiroomi Nagata
  • COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
    Publication number: 20240238205
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Application
    Filed: December 21, 2023
    Publication date: July 18, 2024
    Inventors: Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT
  • Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
    Patent number: 11890378
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: February 6, 2024
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
    Publication number: 20230181470
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Application
    Filed: August 29, 2022
    Publication date: June 15, 2023
    Inventors: Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT
  • Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
    Patent number: 11471413
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: October 18, 2022
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
    Patent number: 11452692
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: September 27, 2022
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO
    Publication number: 20220162160
    Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.
    Type: Application
    Filed: June 25, 2021
    Publication date: May 26, 2022
    Inventors: Stephen Warren Hunt, III, Martin Douglas Phillips, Robert Matunas, Herman Chen, Aimesther Betancourt, Charles Uzarama, Roch Thibert
  • COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
    Publication number: 20220151933
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Application
    Filed: February 3, 2022
    Publication date: May 19, 2022
    Inventors: Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT
  • SOLID ORAL FORMULATIONS OF AMPHOTERICIN B
    Publication number: 20210369615
    Abstract: The present disclosure describes methods of treating infectious diseases with solid dosage forms comprising amphotericin B. In some embodiments, the disclosure provides methods of treating fungal infections and Lesishmania infection.
    Type: Application
    Filed: July 31, 2019
    Publication date: December 2, 2021
    Inventors: Peter HNIK, Roch THIBERT, Aimesther BETANCOURT
  • COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
    Publication number: 20210177762
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Application
    Filed: January 7, 2021
    Publication date: June 17, 2021
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
    Publication number: 20210154146
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Application
    Filed: February 4, 2021
    Publication date: May 27, 2021
    Inventors: Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT
  • Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
    Patent number: 10933020
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof, and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: March 2, 2021
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation
    Patent number: 10925832
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: February 23, 2021
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
    Publication number: 20200289419
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 17, 2020
    Inventors: Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT
  • SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO
    Publication number: 20200255372
    Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.
    Type: Application
    Filed: September 20, 2019
    Publication date: August 13, 2020
    Inventors: Stephen Warren Hunt, III, Martin Douglas Phillips, Robert Matunas, Herman Chen, Aimesther Betancourt, Charles Uzarama, Roch Thibert
  • SOLID ORAL FORMULATIONS OF AMPHOTERICIN B
    Publication number: 20200155583
    Abstract: The present disclosure describes solid dosage forms comprising amphotericin B. Also described herein are methods of treating fungal infections and Lesishmania infections.
    Type: Application
    Filed: February 21, 2018
    Publication date: May 21, 2020
    Inventors: Peter HNIK, Roch THIBERT, Aimesther BETANCOURT
  • COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION
    Publication number: 20200101018
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Application
    Filed: September 27, 2019
    Publication date: April 2, 2020
    Inventors: Aimesther BETANCOURT, Bruce REHLAENDER, Roch THIBERT